For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221130:nRSd0030Ia&default-theme=true
RNS Number : 0030I Benchmark Holdings PLC 30 November 2022
30 November 2022
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Q4 Results
(3 months ended 30 September 2022)
Strong end to FY22 continuing track record of consistent delivery
In compliance with the terms of the Company's unsecured green bond which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the 3
months ended 30 September 2022 (the "period"). All Q4FY22 and Q4FY21 figures
quoted in this announcement are based on unaudited accounts.
This morning the Company published its full year audited results for the 12
months ended 30 September 2022 which can be found
on https://www.benchmarkplc.com/investors
(https://www.benchmarkplc.com/investors) .
Highlights - strong end to the year
· Revenues £42.8m, 15% ahead of the prior year (+6% CER) with
growth across all business areas:
o Genetics - revenues 15% above Q4 2021 (+11% CER) driven by higher sales of
salmon eggs
o Advanced Nutrition - revenues 10% above the prior year (-6% CER) driven by
commercial focus and continued innovation
o Health - revenues +31% above Q4 2021 (+31% CER) driven by increased sales
of Ectosan(â) Vet and CleanTreat(â)
· Adjusted EBITDA of £8.8m, 23% ahead of last year driven by
higher sales, operational efficiencies and continued financial discipline
· Adjusted EBITDA excluding fair value movements from biological
assets 57% ahead
· Refinancing of NOK850m secured bond through the issue of a
NOK750m unsecured green bond
· Post period end, refinancing of $15m RCF with a £20m RCF
expiring in June 2025
· Cash of £35.1m and Liquidity of c £51.1m (cash and available
facility) as at 29th November 2022
£m Q4 FY22 Q4 FY21 % AER % CER(**) FY22 FY21
(full year)
Revenue 42.8 37.3 15% 6% 158.3 125.1
Adjusted
Adjusted EBITDA(1) 8.8 7.1 23% 15% 31.2 19.4
Adj. EBITDA excluding biological asset movements 9.6 6.1 57% 48% 29.6 16.1
Adjusted Operating Profit(2) 3.5 3.5 0% -9% 9.1 10.8
Statutory
Operating (loss)/profit (1.7) 0.5 -460% -524% (7.9) (5.4)
Loss before tax (6.8) (3.2) -109% -127% (23.2) (9.2)
Loss for the Period (8.9) (5.7) -56% -58% (30.5) (11.6)
Basic loss per share (p) (1.36) (0.91) (4.60) (1.93)
Net debt(3) (73.7) (80.9) (73.7) (80.9)
Net debt excluding lease liabilities (47.5) (56.9) (47.5) (56.9)
** Constant exchange rate (CER) figures derived by retranslating current
year figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.
(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Business Area Summary
£m Q4 FY22 Q4 FY21 % AER % CER(**) FY22 FY21
(full year)
Revenue
Advanced Nutrition 18.9 17.1 10% -6% 80.3 70.5
Genetics 18.3 15.9 15% 11% 58.0 46.8
Health 5.6 4.3 31% 31% 20.1 7.8
Adjusted EBITDA(1)
Advanced Nutrition 4.7 3.6 29% 8% 19.0 13.8
Genetics 5.5 3.3 65% 72% 16.0 11.5
- Net of fair value movements in biological assets 6.3 2.3 173% 183% 14.4 8.2
Health 0.6 1.1 -43% -45% 0.1 (2.7)
** Constant exchange rate (CER) figures derived by retranslating current
year figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.
Operational highlights
· Opening of new salmon egg incubation centre in Iceland
· Salmon egg capacity in Norway and Iceland sold out
· Progress in commercialisation of SPR shrimp - client wins in
Indonesia and Vietnam
· Continued positive commercial momentum in Advanced Nutrition and
focus on operational optimisation
· Increased customer use and adoption of Ectosan® Vet and
CleanTreat®
Current trading and outlook - good momentum in line with our expectations
· Good start to the year and positive momentum in the business
· Diversified business and proactive commercial approach create
resilience to ongoing macroeconomic pressures
· Recently announced change in tax regime for aquaculture
producers in Norway expected to have a marginal direct effect
· Continue to progress towards a dual listing on Euronext Growth
Oslo with intention to uplist to the Oslo Børs in H1 2023
Enquiries
For further information, please contact:
Benchmark Holdings plc Tel: 020 3696 0630
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
James Black, Freddie Barnfield, Duncan Monteith
MHP Tel: 020 3128 8004
Katie Hunt, Reg Hoare, Veronica Farah benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.
Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia, in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com
Management Report
The Group reported a strong Q4, continuing the good performance delivered
throughout the year. Group revenues at £42.8m were 15% ahead of the prior
year (+6% CER) reflecting good trading across all business areas despite the
ongoing macroeconomic challenges and price pressure in some of our end
markets. Our three business areas delivered revenue growth, with Advanced
Nutrition growing by 10%, Genetics by 15% and Health by 31%. Advanced
Nutrition continued to capitalise on its renewed commercial focus, Genetics
benefitted from peak demand for its specialist salmon eggs and in Health our
growth reflects the increased customer uptake of our sea lice solution
Ectosan(â) Vet and CleanTreat(â).
Operating costs in Q4 2022 were 30% higher at £13.3m (Q4 2021: £10.2m)
driven by higher activity levels and a strong dollar in the quarter. The
increase was 21% at constant exchange rates. R&D expenses were £2.0m,
10% up driven by small increases in Health and Genetics with R&D spend in
Advanced Nutrition remaining flat against the prior year.
Adjusted EBITDA from continuing operations for the quarter was £8.8m, 23%
ahead of the prior year (Q4FY21: £7.1m) reflecting increased sales,
operational leverage and financial discipline. Excluding fair value movements
from biological assets, Adjusted EBITDA was £9.6m, 57% ahead of the prior
year.
As noted in our full year announcement released today, our net result was
impacted by an increased depreciation charge associated with the leases on the
vessels for our CleanTreat® operation, and higher finance costs due to a
higher interest charge and costs associated with movements of hedging
instruments as well as costs associated with the refinancing of our NOK bond.
Advanced Nutrition
Revenues from Advanced Nutrition were £18.9m, up 10% (-6% CER). By product
area Artemia sales were up 5%, Diets up 20% and sales from Health products
increased by 25% compared to the same period last year. The gross profit
margin grew slightly from 60% to 61%.
Operating costs and R&D totalled £6.8m, up 10% compared to the prior
year. Continued cost discipline and operational improvements resulted in an
increase in Adjusted EBITDA of 29% (+8% CER) to £4.7m. As a result, the
Adjusted EBITDA margin reached 25% (Q4FY21:21%).
Genetics
Genetics performed well in the period with revenues of £18.3m, 15% above the
prior year (Q4 2021: £15.9m) driven by higher sales of salmon eggs resulting
in all of our capacity in our Norway and Iceland facilities being sold out.
Harvest revenues were also higher, and we benefitted from first commercial
revenues of our SPR shrimp compared to last year. The gross profit margin
was 55% (Q4FY21: 42%)
Adjusted EBITDA of £5.5m in the period was 65% higher than the prior year (Q4
2021: £3.3m) primarily from higher sales together with cost discipline
resulting in operational leverage. Excluding the fair value movements from
biological assets Adjusted EBITDA was £6.3m, 173% ahead of the prior year (Q4
FY21: £2.3m). As a result, the Adjusted EBITDA margin excluding biological
asset movements was 35% (Q4 FY21: 15%).
By species, salmon delivered an excellent performance benefitting from peak
demand for our biosecure, specialist eggs available year round and capacity
and quality enhancements from our new incubation centre in Iceland. In
shrimp, we continued to progress in our commercialisation of our recently
launched SPR shrimps with client wins in Indonesia and Vietnam. We continue to
work on developing our product range to the specific needs of the key shrimp
markets.
Health
Health delivered a good performance in Q4, reflecting increased use and
adoption of our sea lice solution Ectosan Vet and CleanTreat. Revenues in the
quarter were £5.6m, up 30% reflecting progress in use and adoption of our
solution. Adjusted EBITDA in the period was £0.6m (Q4FY21: £1.1m). This
reflects the costs associated with having two CleanTreat® units in operation
against one in the same period last year. Operating costs and R&D were
£1.9m in the period (Q4 FY21: £1.5m). Costs associated with the leases of
the vessels for the CleanTreat units amounted to £1.8m.
Finance costs, cashflow and net debt
During the quarter, the existing NOK 850m was refinanced through the issue of
an unsecured NOK 750m green bond with a maturity date in September 2025 and is
to be listed on the Oslo Stock Exchange. The company also extended and
increased its RCF facility from $15m to £20m with maturity in June 2025.
Net finance cost for the quarter of £5.1m was higher than the prior year (Q4
2021: £3.7m). Movements in the quarter in the fair value of our financial
instruments taken out to hedge our external borrowings caused a charge of
£5.3m, (Q4 2021: charge of £0.4m). Interest charges for the period of
£5.3m (Q4 2021: £1.9m) included one-off early bond settlement fees of £1.6m
and accelerated amortisation of previously deferred borrowing fees of £0.9m
following the refinancing of the old bond. These charges were offset in the
quarter by foreign exchange gains of £5.6m (Q4 2021: loss £1.2m) due to
movements in exchange rates towards the end of the year.
Positive operating cashflows from strong trading in the quarter, together with
repayment of some of the borrowings in the refinancing exercise, left net debt
at the quarter end at £73.7m (30 June 2022: £89.1m; 30 Sept 2021:
£80.9m). Net debt excluding lease liabilities was £47.5m (30 June 2022:
£59.3m; 30 Sept 2021: £56.9m).
Outlook
We have had a good start to the year and there is good momentum in the
business. Cost inflation and other macroeconomic pressures will continue to be
a feature across the world in 2023 and we are not immune. However, we have a
well-diversified, balanced business which creates resilience to challenges in
individual markets as well as opportunities. In addition, we will continue to
proactively mitigate potential pressure on our business and our margins
through pricing, supplier management and operational improvements. The
recently announced change in the tax regime for aquaculture producers in
Norway is expected to have a marginal direct effect on our business.
Looking further into the future, Benchmark is uniquely positioned in an
industry that is structurally growing and driven by multiple megatrends. This
creates significant opportunity for growth and increasing returns for
shareholders in the near and medium term and for many years to come.
Consolidated Income Statement for the period ended 30 September 2022
All figures in £000's Notes Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Revenue 4 42,758 37,261 158,277 125,062
Cost of sales (18,625) (17,831) (75,149) (59,477)
Gross profit 24,133 19,430 83,128 65,585
Research and development costs (2,028) (1,838) (6,691) (7,010)
Other operating costs (13,290) (10,195) (44,661) (38,221)
Share of loss of equity-accounted investees, net of tax (57) (299) (595) (905)
Adjusted EBITDA² 8,758 7,098 31,181 19,449
Exceptional - restructuring, disposal and acquisition related items 5 (423) 871 16 (184)
EBITDA¹ 8,335 7,969 31,197 19,265
Depreciation and impairment (4,639) (3,309) (19,897) (8,359)
Amortisation and impairment (5,440) (4,174) (19,161) (16,283)
Operating (loss)/profit (1,744) 486 (7,861) (5,377)
Finance cost (11,547) (3,771) (20,057) (7,987)
Finance income 6,496 40 4,741 4,185
Loss before taxation (6,795) (3,245) (23,177) (9,179)
Tax on loss 6 (2,074) (2,455) (7,274) (2,397)
Loss for the period (8,869) (5,700) (30,451) (11,576)
Loss for the period attributable to:
- Owners of the parent (9,561) (6,101) (32,087) (12,891)
- Non-controlling interest 692 401 1,636 1,315
(8,869) (5,700) (30,451) (11,576)
Earnings per share
Basic loss per share (pence) 7 (1.36) (0.91) (4.60) (1.93)
Diluted loss per share (pence) 7 (1.36) (0.91) (4.60) (1.93)
1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment
2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items
Consolidated Statement of Comprehensive Income for the period ended 30
September 2022
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Loss for the period (8,869) (5,700) (30,451) (11,576)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences 23,225 4,113 47,606 (9,929)
Cash flow hedges - changes in fair value 2,047 760 2,627 3,054
Cash flow hedges - reclassified to profit or loss 2,387 164 2,546 709
Total comprehensive income for the period 18,790 (663) 22,328 (17,742)
Total comprehensive income for the period attributable to:
- Owners of the parent 18,109 (1,026) 20,326 (19,329)
- Non-controlling interest 681 363 2,002 1,587
18,790 (663) 22,328 (17,742)
The accompanying notes are an integral part of this consolidated financial
information.
Consolidated Balance Sheet as at 30 September 2022
30 September 2022 30 September 2021
All figures in £000's Notes (audited) (audited)
Assets
Property, plant and equipment 81,900 78,780
Right-of-use assets 27,034 25,531
Intangible assets 245,264 229,040
Equity-accounted investees 3,113 3,354
Other investments 15 15
Biological and agricultural assets 20,878 21,244
Non-current assets 378,204 357,964
Inventories 29,813 20,947
Biological and agricultural assets 25,780 17,121
Trade and other receivables 56,377 46,498
Cash and cash equivalents 36,399 39,460
Current assets 148,369 124,026
Total assets 526,573 481,990
Liabilities
Trade and other payables (44,324) (46,668)
Loans and borrowings 8 (17,091) (10,654)
Corporation tax liability (10,211) (5,634)
Provisions (1,631) (563)
Current liabilities (73,257) (63,519)
Loans and borrowings 8 (93,045) (109,737)
Other payables (8,996) (911)
Deferred tax (27,990) (28,224)
Non-current liabilities (130,031) (138,872)
Total liabilities (203,288) (202,391)
Net assets 323,285 279,599
Issued capital and reserves attributable to owners of the parent
Share capital 9 704 670
Additional paid-in share capital 9 420,824 400,682
Capital redemption reserve 5 5
Retained earnings (185,136) (154,231)
Hedging reserve (703) (5,876)
Foreign exchange reserve 77,705 30,465
Equity attributable to owners of the parent 313,399 271,715
Non-controlling interest 9,886 7,884
Total equity and reserves 323,285 279,599
The accompanying notes are an integral part of this consolidated financial
information.
Consolidated Statement of Changes in Equity for the period ended 30 September
2022
Share Additional paid-in share capital* Other Hedging Retained Total attributable Non- Total
capital
reserves
reserve
earnings
to equity holders of
controlling
equity
parent
interest
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2021 (audited) 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income for the period
(Loss) for the period - - - - (32,087) (32,087) 1,636 (30,451)
Other comprehensive income - - 47,240 5,173 - 52,413 366 52,779
Total comprehensive income for the period - - 47,240 5,173 (32,087) 20,326 2,002 22,328
Contributions by and distributions to owners
Share issue 34 20,704 - - - 20,738 - 20,738
Share issue costs recognised through equity - (562) - - - (562) - (562)
Share-based payment - - - - 1,182 1,182 - 1,182
Total contributions by and distributions to owners 34 20,142 - - 1,182 21,358 - 21,358
Changes in ownership
Total changes in ownership interests - - - - - - - -
Total transactions with owners of the Company 34 20,142 - - 1,182 21,358 - 21,358
As at 30 September 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
As at 1 October 2020 (audited) 668 399,601 40,683 (9,651) (142,170) 289,131 6,309 295,440
Comprehensive income for the period
(Loss) for the period - - - - (12,891) (12,891) 1,315 (11,576)
Other comprehensive income - - (10,213) 3,775 - (6,438) 272 (6,166)
Total comprehensive income for the period - - (10,213) 3,775 (12,891) (19,329) 1,587 (17,742)
Contributions by and distributions to owners
Share issue 2 1,081 - - - 1,083 - 1,083
Share issue costs recognised through equity - - - - - - - -
Share-based payment - - - - 830 830 - 830
Total contributions by and distributions to owners 2 1,081 - - 830 1,913 - 1,913
Changes in ownership
Acquisition of NCI - - - - - - (12) (12)
Total changes in ownership interests - - - - - - (12) (12)
Total transactions with owners of the Company 2 1,081 - - 830 1,913 (12) 1,901
As at 30 September 2021 (audited) 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve.
Consolidated Statement of Cash Flows for the period ended 30 September 2022
FY 2022 (audited) FY 2021 (audited)
£000 £000
Cash flows from operating activities
Loss for the period (30,451) (11,576)
Adjustments for:
Depreciation and impairment of property, plant and equipment 8,602 5,017
Depreciation and impairment of right-of-use assets 11,295 3,342
Amortisation and impairment of intangible fixed assets 19,161 16,283
Loss on sale of property, plant and equipment (43) 46
Finance income (319) (1,442)
Finance costs 18,437 7,987
Increase in fair value of contingent consideration receivable (1,203) -
Share of loss of equity-accounted investees, net of tax 595 905
Foreign exchange losses (3,985) (1,800)
Share-based payment expense 1,182 830
Other adjustments for non-cash items (276) -
Tax credit 7,274 2,397
Increase in trade and other receivables (8,511) (8,178)
Increase in inventories (5,406) (3,554)
Increase in biological and agricultural assets (6,099) (5,427)
Increase in trade and other payables 6,946 5,547
Increase in provisions 1,058 -
18,257 10,377
Income taxes paid (7,447) (4,587)
Net cash flows generated from operating activities 10,810 5,790
Investing activities
Purchase of investments (378) (578)
Receipts from disposal of investments 1,544 9
Purchases of property, plant and equipment (10,808) (17,683)
Purchase of intangibles (205) (5,038)
Capitalised research and development costs (1,708) -
Proceeds from sale of fixed assets 220 112
Interest received 119 88
Net cash flows used in investing activities (11,216) (23,090)
Financing activities
Proceeds of share issues 20,737 750
Share-issue costs recognised through equity (562) -
Acquisition of NCI - (12)
Proceeds from bank or other borrowings 67,939 -
Repayment of bank or other borrowings (74,874) (3,106)
Interest and finance charges paid (9,629) (7,699)
Repayments of lease liabilities (10,533) (4,602)
Net cash outflow from financing activities (6,922) (14,669)
Net decrease in cash and cash equivalents (7,328) (31,969)
Cash and cash equivalents at beginning of period 39,460 71,605
Effect of movements in exchange rate 4,267 (176)
Cash and cash equivalents at end of period 36,399 39,460
Unaudited notes to the quarterly financial statements for the period ended 30
September 2022
1. Basis of preparation
Benchmark Holdings plc (the 'Company') is a company incorporated domiciled in
the United Kingdom. These consolidated quarterly financial statements as at
and for the three months and year ended 30 September 2022 represents that of
the Company and its subsidiaries (together referred to as the 'Group').
These quarterly financial statements have been prepared in accordance with IAS
34 Interim Financial Reporting and should be read in conjunction with the
Group's consolidated financial statements as at and for the year ended 30
September 2022. They do not include all the information required for a
complete set of IFRS financial statements. However, selected explanatory
notes are included to explain events and transactions that are significant to
an understanding of the changes in the Group's financial position and
performance since the last annual financial statements. Statutory accounts
for the year ended 30 September 2022 were approved by the Directors on 30
November 2022 and will be delivered to the Registrar of Companies after the
AGM on 16 February 2023. The audit report received on those accounts was (i)
unqualified and (ii) did not contain a statement under section 498(2) or (3)
of the Companies Act 2006.
Going concern
The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.
As at 30 September 2022 the Group had net assets of £323.3m (30 September
2021: £279.6m), including cash of £36.4m (30 September 2021: £39.5m) as
set out in the consolidated balance sheet. The Group made a loss for the year
of £30.5m (year ended 30 September 2021: loss £11.6m).
As noted in the Strategic Report, we have seen a year of strong performance
following an extended period impacted by COVID-19, with improvements
throughout the year in all of our three business areas. The Directors have
reviewed forecasts and cash flow projections for a period of at least 12
months including downside sensitivity assumptions in relation to trading
performance across the Group to assess the impact on the Group's trading and
cash flow forecasts and on the forecast compliance with the covenants included
within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and potential supply constraints on CIS artemia in Advanced
Nutrition. Mitigating measures within the control of management have been
identified should they be required in response to these sensitivities,
including reductions in areas of discretionary spend, deferral of capital
projects and temporary hold on R&D for non-imminent products.
The year ended with the successful refinancing of its NOK 850 million bond
which was due to mature in June 2023 with the issue of a NOK 750 million
unsecured green bond maturing in 2025. This was achieved against a backdrop of
challenging macroeconomic and market conditions and places the Group in a much
stronger position in light of the ongoing market environment. Additionally,
following the year end, the USD15m RCF was refinanced with the agreement of a
new GBP20m RCF on 21 November 2022 with a maturity of June 2025 maturity.
Furthermore, our NOK 216m loan facility (which had NOK 165.6m outstanding at
the year end) which was set to mature in October 2023 was combined with our
NOK 17.5m overdraft facility into a new loan facility of NOK 179.5m on 1
November 2022, with a new maturity date in a further 5 years no later than 15
January 2028. Following all of these refinancing transactions, the Directors
are satisfied there are sufficient facilities in place during the assessment
period.
The global economic environment has recently experienced turbulence largely as
a result of the conflict in Eastern Europe with supply issues in a number of
industries impacted and inflation at high levels. Against this backdrop, the
Group shows resilience against these pressures in its forecasts, with
financial instruments in place to fix interest rates and with opportunities
available to mitigate globally high inflation rates, such that even under all
of the above scenario analysis, the Group has sufficient liquidity and
resources throughout the period under review whilst still maintaining adequate
headroom against the borrowing covenants.
The Directors therefore remain confident that the Group has adequate resources
to continue to meet its liabilities as and when they fall due within the
period of 12 months from the date of approval of these financial statements.
Based on their assessment, the Directors believe it remains appropriate to
prepare the financial statements on a going concern basis.
1. Basis of preparation (continued)
These financial statements have been prepared in accordance with international
accounting standards in conformity with the requirements of the Companies Act
2006 and International Financial Reporting Standards adopted pursuant to
Regulation (EC) No 1606/2002 as it applies in the European Union.
The preparation of financial statements in compliance with adopted IFRSs
requires the use of certain critical accounting estimates. It also requires
Group management to exercise judgement in applying the Group's accounting
policies. The areas where significant judgements and estimates have been made
in preparing the financial statements and their effect are disclosed in Note
2.
2. Accounting policies
The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2022.
Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.
Alternative performance measures ('APMs')
The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by EU-adopted IFRS.
These APMs may not be directly comparable with other companies' APMs, and the
Directors do not intend these as a substitute for, or superior to, IFRS
measures.
Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 10).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using
prior year's foreign exchange rates.
Use of estimates and judgements
The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.
In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2022.
3. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
· Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.
· Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
· Health - the segment provides health products and services to the
global aquaculture market.
3. Segment information (continued)
In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy
was applied consistently throughout the current and prior period.
Reconciliations of segmental information to IFRS measures
Segmental Revenue
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Genetics 18,314 15,932 58,008 46,797
Advanced Nutrition 18,872 17,093 80,286 70,530
Health 5,602 4,269 20,135 7,832
Corporate 902 1,209 5,120 4,820
Inter-segment sales (932) (1,242) (5,272) (4,917)
Total 42,758 37,261 158,277 125,062
Segmental Adjusted EBITDA
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Genetics 5,473 3,309 15,980 11,528
Advanced Nutrition 4,706 3,644 19,017 13,802
Health 625 1,104 108 (2,685)
Corporate (2,046) (959) (3,924) (3,196)
Total 8,758 7,098 31,181 19,449
Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
taxation
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Total reportable segment Adjusted EBITDA 10,804 8,057 35,105 22,645
Corporate Adjusted EBITDA (2,046) (959) (3,924) (3,196)
Adjusted EBITDA 8,758 7,098 31,181 19,449
Exceptional - restructuring, disposal and acquisition related items (423) 871 16 (184)
Depreciation and impairment (4,639) (3,309) (19,897) (8,359)
Amortisation and impairment (5,440) (4,174) (19,161) (16,283)
Net finance costs (5,051) (3,731) (15,316) (3,802)
Loss before taxation (6,795) (3,245) (23,177) (9,179)
4. Revenue
The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2022. The Group's revenue is derived from
contracts with customers.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).
Sale of goods and provision of services
3 months ended 30 September 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 17,449 18,852 4,085 - - 40,386
Provision of services 855 - 1,517 - - 2,372
Inter-segment sales 10 20 - 902 (932) -
18,314 18,872 5,602 902 (932) 42,758
3 months ended 30 September 2021 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 14,925 17,077 2,593 - - 34,595
Provision of services 990 - 1,676 - - 2,666
Inter-segment sales 17 16 - 1,209 (1,242) -
15,932 17,093 4,269 1,209 (1,242) 37,261
12 months ended 30 September 2022 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 53,978 80,191 13,528 - - 147,697
Provision of services 3,973 - 6,607 - - 10,580
Inter-segment sales 57 95 - 5,120 (5,272) -
58,008 80,286 20,135 5,120 (5,272) 158,277
12 months ended 30 September 2021 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 41,947 70,458 6,135 - - 118,540
Provision of services 4,825 - 1,697 - - 6,522
Inter-segment sales 25 72 - 4,820 (4,917) -
46,797 70,530 7,832 4,820 (4,917) 125,062
4. Revenue (continued)
Sale of goods and provision of services (continued)
Primary geographical markets
3 months ended 30 September 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 11,151 314 4,204 - - 15,669
India 38 1,074 - - - 1,112
Singapore - 121 - - - 121
Turkey - 1,314 - - - 1,314
Ecuador - 2,606 - - - 2,606
Greece - 931 - - - 931
Faroe Islands 1,539 2 209 - - 1,750
UK 1,099 26 33 - - 1,158
Chile 237 8 222 - - 467
Rest of Europe 2,158 844 - - - 3,002
Rest of World 2,082 11,612 934 - - 14,628
Inter-segment sales 10 20 - 902 (932) -
18,314 18,872 5,602 902 (932) 42,758
3 months ended 30 September 2021 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 10,526 135 2,898 - - 13,559
India - 3,029 - - - 3,029
Singapore - 1,954 - - - 1,954
Greece - 986 - - - 986
Faroe Islands 1,171 2 180 - - 1,353
Turkey - 1,109 - - - 1,109
UK 276 20 145 - - 441
Ecuador - 1,057 - - - 1,057
Chile 400 1 296 - - 697
Rest of Europe 2,347 763 - - - 3,110
Rest of World 1,195 8,021 750 - - 9,966
Inter-segment sales 17 16 - 1,209 (1,242) -
15,932 17,093 4,269 1,209 (1,242) 37,261
4. Revenue (continued)
Primary geographical markets (continued)
12 months ended 30 September 2022 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 34,666 965 15,571 - - 51,202
India 619 12,001 - - - 12,620
Singapore - 7,044 - - - 7,044
Turkey - 6,419 - - - 6,419
Ecuador 18 6,472 - - - 6,490
Greece 2 6,197 - - - 6,199
Faroe Islands 5,465 9 587 - - 6,061
UK 4,318 93 199 - - 4,610
Chile 1,006 15 871 - - 1,892
Rest of Europe 7,110 4,056 - - - 11,166
Rest of World 4,747 36,920 2,907 - - 44,574
Inter-segment sales 57 95 - 5,120 (5,272) -
58,008 80,286 20,135 5,120 (5,272) 158,277
12 months ended 30 September 2021 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 27,129 570 3,689 - - 31,388
India - 12,166 3 - - 12,169
Singapore - 7,544 - - - 7,544
Greece 25 6,108 - - - 6,133
Faroe Islands 5,636 18 348 - - 6,002
Turkey - 5,977 - - - 5,977
UK 3,843 117 622 - - 4,582
Ecuador - 4,066 - - - 4,066
Chile 437 7 2,335 - - 2,779
Rest of Europe 6,922 4,208 26 - - 11,156
Rest of World 2,780 29,677 809 - - 33,266
Inter-segment sales 25 72 - 4,820 (4,917) -
46,797 70,530 7,832 4,820 (4,917) 125,062
5. Exceptional - restructuring, disposal, and acquisition related
items
Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Acquisition related items - (850) - (850)
Exceptional restructuring costs 1,668 110 1,229 480
Cost in relation to disposals (1,245) (131) (1,245) 554
Total exceptional items 423 (871) (16) 184
Acquisition-related items are costs incurred in investigating and acquiring
new businesses. In 2021 contingent consideration of £850,000 was released in
relation to the purchase of Benchmark Genetics (USA) Inc.
Exceptional costs include: £843,000 (2021: £nil) of legal and professional
costs in relation to preparing for listing the Group on the Oslo stock
exchange, and £276,000 (2021: £480,000) relating to restructuring costs.
Costs in relation to disposals includes a credit of £1,203,000 (2021: £nil)
in relation to additional contingent consideration received and receivable
from disposals in previous years (£294,000 relating to the disposal of
Aquaculture UK on 7 February 2020, and £909,000 relating to the disposal of
Improve International Limited and its subsidiaries on 23 June 2020) together
with legal fees, lease costs and disposal items (net of proceeds received)
totaling £42,000 relating to additional costs and disposals proceeds relating
to disposals that occurred in 2020.
6. Taxation
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Analysis of charge in period
Current tax:
Current income tax expense on profits for the period 4,124 2,716 11,727 5,383
Adjustment in respect of prior periods (39) 502 (39) 502
Total current tax charge 4,085 3,218 11,688 5,885
Deferred tax:
Origination and reversal of temporary differences (2,011) (768) (4,414) (3,228)
Deferred tax movements in respect of prior periods - 5 - (260)
Total deferred tax credit (2,011) (763) (4,414) (3,488)
Total tax charge 2,074 2,455 7,274 2,397
7. Loss per share
Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.
Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Loss attributable to equity holders of the parent (£000) (9,561) (6,101) (32,087) (12,891)
Weighted average number of shares in issue (thousands) 703,961 670,141 698,233 669,459
Basic loss per share (pence) (1.36) (0.91) (4.60) (1.93)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.
Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.
A total of 6,240,304 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2021: 4,615,712). These potential ordinary shares could dilute earnings/loss
per share in the future.
8. Loans and borrowings
All figures in £000's FY 2022 FY 2021
(audited)
(audited)
Non-Current
2025 750m NOK Loan notes 61,054 -
2023 850m NOK Loan notes - 75,478
Bank borrowings 17,226 19,314
Lease liabilities 14,765 14,945
93,045 109,737
Current
Bank borrowings 5,569 1,612
Lease liabilities 11,522 9,042
17,091 10,654
Total loans and borrowings 110,136 120,391
At 30 September 2022 the fair value of the unsecured floating rate listed
green bond of NOK 750m was not materially different to the nominal value and
has not been separately disclosed. At 30 September 2021 the fair value of 2023
850m NOK Loan notes was £73,981,000.
On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments, and is to be listed on the Oslo Stock Exchange. The proceeds were
used to repay the NOK 850m floating rate listed bond, originally raised in
June 2019.
A USD 15m Revolving Credit Facility ("RCF") has been provided by DNB Bank ASA
(50%) and HSBC UK Bank PLC (50%). At 30 September 2022 £4,000,000 was drawn
on this facility. The facility was undrawn at 30 September 2021.
8. Loans and borrowings (continued)
Benchmark Genetics Salten AS (formerly SalmoBreed Salten AS) had the following
loans (which are ring-fenced debt without recourse to the remainder of the
Group) at 30 September 2022:
- Term loan with a balance of NOK 165.6m (2021: NOK 180.0m)
provided by Nordea Bank Norge Abp. The loan is a five-year term loan ending
November 2023 at an interest rate of 2.5% above three-month NIBOR.
- NOK 20.0m 12-month working capital facility provided by Nordea
Bank Norge Abp. This was undrawn at 30 September 2022 (2021: undrawn).
- An additional NOK 17.5m overdraft facility was provided by
Nordea Bank Norge Abp during the year with maturity in December 2022. This
facility was undrawn at 30 September 2022.
- Term loan with a balance of NOK 40.1m (2021: NOK 44.7m) provided
by Innovasjon Norge. The loan is a 12-and-a-half-year term loan maturing in
March 2031. The interest rate on this loan at 30 September 2022 was 4.95%. The
interest rate on this loan is variable.
- NOK 21.75m loan provided by Salten Aqua ASA (the minority
shareholder). The loan attracts interest at 2.5% above three-month NIBOR and
is repayable on maturity of the Nordea term loan above.
Subsequent to the year end on 1 November 2022, the Nordea Bank term loan above
was refinanced together with an existing undrawn overdraft facility into a new
loan facility of NOK 179.5m with a new maturity date in a further five years
no later than 15 January 2028. Other terms remain the same.
Furthermore on 21 November 2022, the Group refinanced the USD15m RCF with a
secured GBP20m RCF provided by DNB Bank ASA, maturing on 27 June 2025. The
margin on this facility is a minimum of 2.75% and a maximum of 3.25%,
dependent upon the leverage of the Group above the relevant risk free
reference or IBOR rates depending on which currency is drawn.
The lease liabilities are secured on the assets to which they relate.
9. Share capital and additional paid-in share capital
Number Share Capital Additional paid-in
share capital
Allotted, called up and fully paid £000 £000
Ordinary shares of 0.1 pence each
Balance at 30 September 2021 670,374,484 670 400,682
Shares issued through placing and open offer 33,401,620 34 20,069
Exercise of share options 184,694 - 73
Balance at 30 September 2022 703,960,798 704 420,824
During the year ended 30 September 2022, the Group issued a total 184,694
ordinary shares of 0.1p each to certain employees of the Group relating to
share options of which 12,509 were exercised at a price of 0.1 pence, and
172,185 were exercised at a price of 42.5p.
On 29 November 2021, the Company issued 33,401,620 new ordinary shares of 0.1
pence each by way of a placing and subscriptions at an issue price of 62.0
pence per share. Gross proceeds of £20.7m were received for the placing and
subscription shares. Non-recurring costs of £0.6m were in relation to the
share issues and this has been charged to the share premium account (presented
within Additional paid-in share capital).
During the year ended 30 September 2021, the Group issued a total of 2,152,600
ordinary shares of 0.1p each to certain employees of the Group relating to
share options, of which 426,182 were exercised at a price of 0.1 pence,
1,626,436 were exercised at a price of 42.5 pence and 99,982 were exercised at
a price of 58.5 pence.
During the prior year, contingent consideration totalling USD 450,000
(£333,000) became payable following the acquisition of aquaculture breeding
programmes centred on shrimp from Centro de Investigación de la Acuicultura
de Colombia Ceniacua on 11 August 2016. At the Group's discretion, the
contingent consideration was paid in ordinary shares in the Group and the
Group therefore issued 536,272 ordinary shares of 0.1p each on 13 January 2021
to settle this liability.
10. Alternative performance measures and other metrics
Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.
Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
including acquisition related items and is shown on the Income Statement.
Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.
Adjusted Operating Profit is operating loss before exceptional items including
acquisition related items and amortisation and impairment of intangible assets
excluding development costs as reconciled below.
Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items
including acquisition related items as reconciled below. These measures are
not defined performance measures in IFRS. The Group's definition of these
measures may not be comparable with similarly titled performance measures and
disclosures by other entities.
Reconciliation of Adjusted Operating Profit to Operating Loss
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Revenue 42,758 37,261 158,277 125,062
Cost of sales (18,625) (17,831) (75,149) (59,477)
Gross profit 24,133 19,430 83,128 65,585
Research and development costs (2,028) (1,838) (6,691) (7,010)
Other operating costs (13,290) (10,195) (44,661) (38,221)
Depreciation and impairment (4,639) (3,309) (19,897) (8,359)
Amortisation of capitalised development costs (615) (299) (2,165) (299)
Share of loss of equity accounted investees net of tax (57) (299) (595) (905)
Adjusted operating profit 3,504 3,490 9,119 10,791
Exceptional - restructuring, disposal and acquisition related items (423) 871 16 (184)
Amortisation and impairment of intangible assets excluding development costs (4,825) (3,875) (16,996) (15,984)
Operating (loss)/profit (1,744) 486 (7,861) (5,377)
Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Loss before taxation (6,795) (3,245) (23,177) (9,179)
Exceptional - restructuring, disposal and acquisition related items 423 (871) (16) 184
Amortisation and impairment of intangible assets excluding development costs 4,825 3,875 16,996 15,984
Adjusted (loss)/profit before tax (1,547) (241) (6,197) 6,989
10. Alternative performance measures and other metrics (continued)
Other
Metrics
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Total R&D Investment
Research and development costs 2,028 1,838 6,691 7,010
Internal capitalised development costs 112 1,351 1,708 4,813
Total R&D investment 2,140 3,189 8,399 11,823
All figures in £000's Q4 2022 Q4 2021 FY 2022 FY 2021
(unaudited)
(unaudited)
(audited)
(audited)
Adjusted EBITDA excluding fair value movement in biological assets
Adjusted EBITDA 8,758 7,098 31,181 19,449
Exclude fair value movement 848 (996) (1,595) (3,323)
Adjusted EBITDA excluding fair value movement in biological assets 9,606 6,102 29,586 16,126 16,126
Liquidity
A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.
30 September 2022
All figures in £000's (audited)
Cash and cash equivalents 36,399
Undrawn bank facility 9,398
45,797
The undrawn bank facility relates to the RCF facility. At 30 September 2022,
£4,000,000 (2021: £nil) of the RCF was drawn, leaving £9.4m undrawn (2021:
£11.1m).
11. Net debt
Net debt is cash and cash equivalents less loans and borrowings.
30 September 2022 30 September 2021
All figures in £000's (audited) (audited)
Cash and cash equivalents 36,399 39,460
Loans and borrowings (excluding lease liabilities) - current (5,569) (1,612)
Loans and borrowings (excluding lease liabilities) - non-current (78,280) (94,792)
Net debt excluding lease liabilities (47,450) (56,944)
Lease liabilities - current (11,522) (9,042)
Lease liabilities - non-current (14,765) (14,945)
Net debt (73,737) (80,931)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FR EADFNAFKAFAA